Morgan Stanley Maintains Overweight on Kymera Therapeutics, Raises Price Target to $146
Benzinga Newsdesk 4 days ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst James Quigley maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $135 to $146.
Morgan Stanley analyst James Quigley maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $135 to $146.